Tuesday, November 17, 2026 | 07:13 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 4 - Gland Pharma

Gland Pharma tanks 20%, hits record low on weak Q4 results

Revenue declined 29% YoY due to lower offtake of the key products in developed as well as domestic markets and due to Production line shut down in Pashamylaram Penems facility due to line upgradation.

Gland Pharma tanks 20%, hits record low on weak Q4 results
Updated On : 19 May 2023 | 10:17 AM IST

Gland Pharma profit declines by 56% on soft demand in March quarter

Its earnings before interest, taxes, depreciation, and amortisation (EBITDA) margin contracted to 21% from 32% a year earlier

Gland Pharma profit declines by 56% on soft demand in March quarter
Updated On : 18 May 2023 | 7:29 PM IST

ITC, SBI, and others: These companies will declare their Q4 results today

Q4 results today: The list of companies that will declare their financial results has names like IndiGo, Jet Airways, Tata Elxsi, and GAIL

ITC, SBI, and others: These companies will declare their Q4 results today
Updated On : 18 May 2023 | 10:07 AM IST

China's Fosun drops plan to sell stake in drugmaker Gland Pharma: Report

Fosun Pharma holds a 57.86% stake in the Indian company

China's Fosun drops plan to sell stake in drugmaker Gland Pharma: Report
Updated On : 26 Apr 2023 | 1:55 PM IST

Gland Pharma Q3 net declines 15% to Rs 232 cr due to production delays

Gland Pharma Ltd on Monday reported a 15 per cent decline in consolidated net profit at Rs 231.95 crore for the third quarter ended December 2022, impacted by production delays due to supply disruptions. The company had posted a consolidated net profit of Rs 273.03 crore in the same period last fiscal, Gland Pharma said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 938.29 crore as against Rs 1,063.33 crore in the year-ago period. Total expenses in the third quarter were lower at Rs 688.95 crore as compared to Rs 743.43 crore in the same period a year ago. "Challenging business environment, ongoing supply chain disruptions leading to production delays continue to impact our performance," Gland Pharma Managing Director and CEO Srinivas Sadu said. The company's core markets US, Europe, Canada, Australia, and New Zealand accounted for 70 per cent of revenue during the quarter, maintaining a similar level of revenue contributio

Gland Pharma Q3 net declines 15% to Rs 232 cr due to production delays
Updated On : 23 Jan 2023 | 8:13 PM IST

Drug firm Gland Pharma to fully acquire Europe-based Cenexi Group

Drug firm Gland Pharma on Friday said it has inked a pact with FPCI Sino French Midcap Fund to acquire 100 per cent stake in Europe-based Cenexi Group. Gland Pharma International PTE, a Singapore-based wholly owned subsidiary of the company, has entered into a share purchase agreement with FPCI Sino French Midcap Fund to fully acquire stake in Cenexi pursuant to the terms of the put option agreement inked in November last year. On November 29, 2022, the Hyderabad-based drug contract development and manufacturing company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to EUR 120 million (around Rs 1,015 crore), marking its foray into the international markets. Under the put option, an entity gets the right not obligation to sell a specified amount or stake at a predetermined price. Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of contract development and manufacturing organisation (CDMO) of pharmaceutical ...

Drug firm Gland Pharma to fully acquire Europe-based Cenexi Group
Updated On : 06 Jan 2023 | 10:45 PM IST

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report
Updated On : 13 Dec 2022 | 3:22 PM IST

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Gland Pharma stock seen underperforming after acquiring France's Cenexi
Updated On : 30 Nov 2022 | 11:29 PM IST

Gland Pharma enters into agreement to acquire Cenexi; stock slips 5%

The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones, the company said

Gland Pharma enters into agreement to acquire Cenexi; stock slips 5%
Updated On : 30 Nov 2022 | 11:16 AM IST

Stocks to Watch: Zomato, SBI, Adani Group, Britannia, ONGC, Gland Pharma

Stocks to Watch Today: According to reports, Zomato is likely to witness a block deal on Wednesday.

Stocks to Watch: Zomato, SBI, Adani Group, Britannia, ONGC, Gland Pharma
Updated On : 30 Nov 2022 | 8:05 AM IST

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma
Updated On : 29 Nov 2022 | 11:21 PM IST
Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore
Updated On : 29 Nov 2022 | 11:19 PM IST

Fosun reportedly planning sale of India's $3.6 billion Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland

Fosun reportedly planning sale of India's $3.6 billion Gland Pharma
Updated On : 29 Nov 2022 | 6:01 PM IST

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock

The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock
Updated On : 27 Oct 2022 | 10:25 PM IST

Gland Pharma plunges 13%, hits 52-week low on disappointing Q2 results

Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin contracted 150 bps to 33 per cent from 38 per cent in a year ago quarter.

Gland Pharma plunges 13%, hits 52-week low on disappointing Q2 results
Updated On : 27 Oct 2022 | 11:15 AM IST

Gland Pharma's Q2 net dips 20.14% to Rs 241.24 cr; India revenue down 42%

Gland Pharma Ltd on Wednesday reported a 20.14 per cent decline in consolidated net profit at Rs 241.24 crore for the second quarter ended September 30, on lower sales and higher expenses. The company had posted a consolidated net profit of Rs 302.08 crore in the same period last fiscal, Gland Pharma said in a regulatory filing. The consolidated revenue from operations during the period under review were at Rs 1,044.4 crore, as against Rs 1,080.47 crore in the year-ago period, it added. Total expenses were higher at Rs 785.95 crore, as compared to Rs 731 crore in the same period a year ago, the company said. Gland Pharma said revenue from its core markets of US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal. However, India revenue was down 42 per cent at Rs 72.6 crore, as compared to Rs 125.8 crore in the year-ago quarter, while the same for the 'rest of the world' market w

Gland Pharma's Q2 net dips 20.14% to Rs 241.24 cr; India revenue down 42%
Updated On : 26 Oct 2022 | 6:13 PM IST

Here's why Mehul Kothari recommends buying Gland Pharma, Indian Oil

According to the technical analyst from Anand Rathi, Gland Pharma can rally to Rs 2,350, while IOC can spurt to Rs 83.

Here's why Mehul Kothari recommends buying Gland Pharma, Indian Oil
Updated On : 14 Oct 2022 | 8:16 AM IST

Stocks to watch: Titan, Dr Reddy's, Nelco, IOC, GIC Housing, Torrent Pharma

Stocks to watch today: Titan plans to add 20 to 30 Tanishq stores over two to three years in the Middle East and North America; Nelco inked pact with Intelsat to provide inflight connectivity services

Stocks to watch: Titan, Dr Reddy's, Nelco, IOC, GIC Housing, Torrent Pharma
Updated On : 26 Aug 2022 | 8:06 AM IST

Gland Pharma faces a revenue growth hurdle in FY23; stock falls

The low margin syringes business was impacted by supply chain challenges and shutdown of two manufacturing lines in the domestic market

Gland Pharma faces a revenue growth hurdle in FY23; stock falls
Updated On : 21 Jul 2022 | 11:34 PM IST

Gland Pharma slips 10%, hits 52-week low on disappointing Q1 results

Q1 profit after tax tumbled 35 per cent YoY and 20 per cent QoQ to Rs 229 crore, due to lower operational income

Gland Pharma slips 10%, hits 52-week low on disappointing Q1 results
Updated On : 21 Jul 2022 | 10:04 AM IST